[go: up one dir, main page]

GB201615908D0 - Pharmaceautical composition - Google Patents

Pharmaceautical composition

Info

Publication number
GB201615908D0
GB201615908D0 GBGB1615908.9A GB201615908A GB201615908D0 GB 201615908 D0 GB201615908 D0 GB 201615908D0 GB 201615908 A GB201615908 A GB 201615908A GB 201615908 D0 GB201615908 D0 GB 201615908D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceautical
composition
pharmaceautical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1615908.9A
Other versions
GB2554088A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mexichem Fluor SA de CV
Original Assignee
Mexichem Fluor SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Fluor SA de CV filed Critical Mexichem Fluor SA de CV
Priority to GB1615908.9A priority Critical patent/GB2554088A/en
Publication of GB201615908D0 publication Critical patent/GB201615908D0/en
Priority to MYPI2023001168A priority patent/MY210122A/en
Priority to CA3037257A priority patent/CA3037257C/en
Priority to MYPI2019001314A priority patent/MY202030A/en
Priority to ES17777636T priority patent/ES2841649T5/en
Priority to NZ752434A priority patent/NZ752434B2/en
Priority to EP19199776.6A priority patent/EP3610877A1/en
Priority to EP17777636.6A priority patent/EP3515451B2/en
Priority to PCT/GB2017/052762 priority patent/WO2018051131A1/en
Priority to BR112019005113-9A priority patent/BR112019005113B1/en
Priority to PE2019000675A priority patent/PE20191044A1/en
Priority to AU2017328908A priority patent/AU2017328908B2/en
Priority to EP19199786.5A priority patent/EP3607951A1/en
Priority to JP2019515271A priority patent/JP6781832B2/en
Priority to UAA201902773A priority patent/UA124240C2/en
Priority to US16/334,156 priority patent/US20190388436A1/en
Priority to CN201780057285.4A priority patent/CN109789151A/en
Priority to MX2019003103A priority patent/MX2019003103A/en
Priority to CN202110273940.8A priority patent/CN113069417A/en
Priority to PH1/2019/500577A priority patent/PH12019500577B1/en
Priority to KR1020197010383A priority patent/KR102279445B1/en
Priority to GEAP201715034A priority patent/GEP20217240B/en
Priority to CN202310774818.8A priority patent/CN116898804A/en
Priority to IL265349A priority patent/IL265349B2/en
Priority to EA201990501A priority patent/EA201990501A1/en
Publication of GB2554088A publication Critical patent/GB2554088A/en
Priority to CONC2019/0002555A priority patent/CO2019002555A2/en
Priority to ZA2019/02052A priority patent/ZA201902052B/en
Priority to US16/582,964 priority patent/US20200016175A1/en
Priority to US16/582,710 priority patent/US20200016174A1/en
Priority to JP2020042092A priority patent/JP6980050B2/en
Priority to AU2020202651A priority patent/AU2020202651C1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1615908.9A 2016-09-19 2016-09-19 Pharmaceautical composition Withdrawn GB2554088A (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GB1615908.9A GB2554088A (en) 2016-09-19 2016-09-19 Pharmaceautical composition
EA201990501A EA201990501A1 (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION
UAA201902773A UA124240C2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
US16/334,156 US20190388436A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MYPI2019001314A MY202030A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
ES17777636T ES2841649T5 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
NZ752434A NZ752434B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
EP19199776.6A EP3610877A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
EP17777636.6A EP3515451B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
PCT/GB2017/052762 WO2018051131A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MX2019003103A MX2019003103A (en) 2016-09-19 2017-09-18 Pharmaceutical composition.
PE2019000675A PE20191044A1 (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION
AU2017328908A AU2017328908B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
EP19199786.5A EP3607951A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
JP2019515271A JP6781832B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MYPI2023001168A MY210122A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
CN201780057285.4A CN109789151A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
CN202110273940.8A CN113069417A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
BR112019005113-9A BR112019005113B1 (en) 2016-09-19 2017-09-18 PHARMACEUTICAL COMPOSITION
CA3037257A CA3037257C (en) 2016-09-19 2017-09-18 Pharmaceutical compositions comprising beclomethasone dipropionate, and formoterol fumarate dihydrate
PH1/2019/500577A PH12019500577B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
KR1020197010383A KR102279445B1 (en) 2016-09-19 2017-09-18 pharmaceutical composition
GEAP201715034A GEP20217240B (en) 2016-09-19 2017-09-18 Pharmaceutical composition
CN202310774818.8A CN116898804A (en) 2016-09-19 2017-09-18 pharmaceutical composition
IL265349A IL265349B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
CONC2019/0002555A CO2019002555A2 (en) 2016-09-19 2019-03-19 Pharmaceutical composition
ZA2019/02052A ZA201902052B (en) 2016-09-19 2019-04-02 Pharmaceutical composition
US16/582,964 US20200016175A1 (en) 2016-09-19 2019-09-25 Pharmaceutical composition
US16/582,710 US20200016174A1 (en) 2016-09-19 2019-09-25 Pharmaceutical composition
JP2020042092A JP6980050B2 (en) 2016-09-19 2020-03-11 Pharmaceutical composition
AU2020202651A AU2020202651C1 (en) 2016-09-19 2020-04-20 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1615908.9A GB2554088A (en) 2016-09-19 2016-09-19 Pharmaceautical composition

Publications (2)

Publication Number Publication Date
GB201615908D0 true GB201615908D0 (en) 2016-11-02
GB2554088A GB2554088A (en) 2018-03-28

Family

ID=57288606

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1615908.9A Withdrawn GB2554088A (en) 2016-09-19 2016-09-19 Pharmaceautical composition

Country Status (1)

Country Link
GB (1) GB2554088A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221867A1 (en) * 2020-01-28 2022-12-02 Chiesi Farm Spa PRESSURIZED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions

Also Published As

Publication number Publication date
GB2554088A (en) 2018-03-28

Similar Documents

Publication Publication Date Title
GB201621987D0 (en) Novel composition
GB201600075D0 (en) Immunogenci composition
PL3443034T3 (en) Composition
GB201621685D0 (en) Novel composition
GB201612658D0 (en) Composition
GB201617908D0 (en) Composition
GB201611782D0 (en) Composition
ZA201901222B (en) Composition comprising duddingtonia flagrans
GB2557410B (en) Composition
GB201620701D0 (en) Novel composition
GB201612359D0 (en) Composition
GB201620846D0 (en) Composition
GB201615908D0 (en) Pharmaceautical composition
GB201607924D0 (en) Composition
GB201620914D0 (en) Composition
GB201620792D0 (en) Composition
GB201619630D0 (en) Composition
GB201618062D0 (en) Composition
GB201616772D0 (en) Composition
GB201616785D0 (en) Composition
GB201615461D0 (en) Composition
GB201615463D0 (en) Composition
GB201615383D0 (en) Composition
GB201615045D0 (en) Composition
GB201614231D0 (en) Composition

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)